Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 25,165

Document Document Title
WO/2018/128390A1
The present invention relates to a method for producing a 5-(3,6-dihydro-2,6-dioxo-4-trifluoromethyl-1(2H)-pyrimidinyl )phenylthiol compound. The production method according to the present invention enables provision of stable yield and ...  
WO/2018/128387A1
The present invention relates to a method for producing a 3-arly uracil compound. The production method according to the present invention can efficiently produce a 3-arly uracil compound by reducing a reaction time for the production of...  
WO/2018/128720A1
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.  
WO/2018/125961A1
The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method o...  
WO/2018/124000A1
The present invention addresses the problem of providing a compound that, when used in the treatment of cystic fibrosis, which is caused by a mutation of a cystic fibrosis transmembrane conductance regulator (CFTR), which is a kind of ch...  
WO/2018/122775A1
The application is directed to compounds of formula (I): and their salts and solvates, wherein R1, R2, R3, A1, A2, A3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions...  
WO/2018/124088A1
Provided are novel pest control agents, in particular, a bactericide and a nematicide. An alkylphenyl-substituted amide compound represented by formula (I) [wherein: G1 stands for a structure represented by G1-2, G1-3, G1-4, etc.; X1 sta...  
WO/2018/122559A1
The present invention relates to compounds which are of use in the field of agriculture as herbicides. The invention also relates to methods of using said compounds and compositions comprising said compounds.  
WO/2018/121758A1
Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.  
WO/2018/113584A1
Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and ca...  
WO/2018/114476A1
The present invention relates to an amidine containing at least one structure unit of formula (I) and to the use thereof as a catalyst for the cross-linking of a functional compound, in particular a polymer comprising silane groups. In a...  
WO/2018/115380A1
The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this...  
WO/2018/119183A2
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.  
WO/2018/118668A1
Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benz enesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are phar...  
WO/2018/107201A1
The invention relates to functionalized dihydro— and tetrahydro-quinazoline compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as heparanase inhibitors for the treatment of diseases or condi...  
WO/2018/108671A1
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description. The com...  
WO/2018/111738A1
Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonist...  
WO/2018/111990A1
The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for treating LHRH-R expressing cancer in a patient. The present teachings relate generally ...  
WO/2018/107200A1
The invention relates to functionalized quinazoline compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as heparanase inhibitors for the treatment of diseases or conditions related to heparanse...  
WO/2018/106606A1
The present disclosure relates to a class of pyrimidine derivatives having immunomodulating properties that act via TLR7 which are useful in the treatment of viral infections and cancers.  
WO/2018/106284A1
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...  
WO/2018/102455A1
Disclosed herein are methods of treating cancer in a subject, wherein the subject is known to possess at least one genetic alteration in RET, comprising administering to the subject a therapeutically effective amount of N-[3-[(6,7-dimeth...  
WO/2018/102366A1
The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.  
WO/2018/100515A1
The invention relates to novel ruthenium complexes of formula (9). The invention also relates to the method for preparation of novel metal complexes of formula (9) and their use in olefin metathesis reactions.  
WO/2018/098348A1
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase inhibitor and (b) a CD38 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in ...  
WO/2018/096497A1
The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, form...  
WO/2018/095390A1
An organic compound, applications thereof, an organic mixture, and an organic electronic device. The structure of the organic compound is represented by general formula (1), and definitions of substituent groups in the general formula (1...  
WO/2018/098250A1
The present invention provides a compound of formula (I) wherein X, Y, Z1, Z2, R1, R2, A, B, p and q are as disclosed in the specification. A pharmaceutical composition and a method for modulating the Hedgehog pathway are also provided. ...  
WO/2018/098446A1
In one aspect, described herein is an intronic recognition element for splicing modifier (iREMS) that can be recognized by a compound provided herein. In another aspect, described herein are methods for modulating the amount of a product...  
WO/2018/098204A1
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.  
WO/2018/095488A1
The invention relates to sulfobetaine compounds, a process for synthesizing same, and the uses of sulfobetaine compounds for synthesizing antimicrobial materials, antistatic materials, antifouling materials, printing inks, surface-active...  
WO/2018/096873A1
[Problem] The purpose of the present invention is to provide a polymerizable liquid crystal compound for constituting a retardation film that has a low liquid crystal phase transition temperature and may preferably have reverse-wavelengt...  
WO/2018/098209A1
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.  
WO/2018/098484A1
The present invention includes a molecule, a method of identifying said molecule, and a method of using said molecule to inhibit the interaction of Αβ and Drpl proteins. The molecules including diethyl (3,4-dihydroxyphenethylamine)(qui...  
WO/2018/092107A1
Novel anti-Viral and anti-Cancer molecule containing nucleobase or its derivatives or its analogues attached to an Ascorbic Acid molecule or its derivatives or its analogues with or without an oxygen bond in-between.  
WO/2018/093579A1
Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions...  
WO/2018/094028A1
A ureido-pyrimidinone oligomer having the formula (I) wherein each Z' is independently the same or different, and is a substituted or unsubstituted straight or branched chain C1-10 alkyl, each R1 is independently the same or different, a...  
WO/2018/090973A1
Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related conditi...  
WO/2018/086585A8
Disclosed in the present invention are nitrogen-containing heterocyclic compounds, a preparation method therefor, a pharmaceutical composition thereof, and applications thereof. The nitrogen-containing heterocyclic compounds represented ...  
WO/2018/085962A1
Disclosed in the present invention are a base acetamide glycerin ether molecule, a chemical synthesis method therefor, and applications thereof in the field of gene delivery. The molecule has an amphiphilic structure represented by formu...  
WO/2018/088749A1
The present invention relates to a novel pyrimidine compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer and inflammatory diseases. The ...  
WO/2018/086585A1
Disclosed in the present invention are nitrogen-containing heterocyclic compounds, a preparation method therefor, a pharmaceutical composition thereof, and applications thereof. The nitrogen-containing heterocyclic compounds represented ...  
WO/2018/086593A1
Disclosed are a nitrogen-containing heterocyclic compound, a preparation method, an intermediate, a pharmaceutical composition and a use. The nitrogen-containing heterocyclic compound of the present invention has a novel structure, relat...  
WO/2018/083053A1
The present invention relates to fluoranthenyl-amine compounds according to a formula (I). Said compounds are suitable for use in electronic devices. The invention also relates to a method for producing said compounds, and to electronic ...  
WO/2018/084321A1
The purpose of the present invention is to develop a safe covalent drug having little fear of side effects by searching for a reactive group having lower reactivity as a substitute for a Michael acceptor and by designing a drug molecule ...  
WO/2018/085674A1
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinazoline structure which function as dual inhibitors EGFR and PI3K, and their use as therapeutics f...  
WO/2018/081585A1
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an aurora kinase inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such com...  
WO/2018/072707A1
The present invention relates to an aromatic ether derivative, a preparation method therefor, and medical applications thereof. Specifically, the present invention relates to a new compound represented by general formula (VIII), a pharma...  
WO/2018/074565A1
Provided is a novel compound having a P2X7 receptor inhibitory action, and a pharmaceutical composition having a P2X7 receptor inhibitory action. a compound represented by Formula (I), or a pharmaceutically acceptable salt or the like th...  
WO/2018/068357A1
Disclosed are a compound as shown in formula I, or a pharmaceutically acceptable salt, a crystal form, a solvate thereof, wherein Z is selected from (II), (III), (IV) or (V); R1 is selected from H or (VI); R2 is selected from (VII) or (V...  

Matches 1 - 50 out of 25,165